Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma - Summary - MDSpire

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

  • By

  • Rakesh Popat

  • Bradley Augustson

  • Mercedes Gironella

  • Cindy Lee

  • Paul Cannell

  • Nashita Patel

  • Ravi S. Kasinathan

  • Rachel Rogers

  • Mehreen Shaikh

  • Amy Curry

  • Fernando Carreño

  • Sumita Roy-Ghanta

  • Joanna Opalinska

  • Hang Quach

  • October 21, 2024

  • 0 min

Share

Objective:

To evaluate the safety and efficacy of belantamab mafodotin in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma during Phase 1/2 of the DREAMM-6 trial.

Key Findings:
  • No DLTs reported in any cohort during dose escalation.
  • Overall safety profile was consistent across cohorts; common Grade 3/4 AEs included keratopathy (53%) and infections (67%).
  • ORR was 67% with a complete response rate of 29%, indicating significant efficacy compared to existing treatments.
  • Median progression-free survival (PFS) was 18.4 months.
Interpretation:

Belantamab mafodotin combined with lenalidomide and dexamethasone shows promising efficacy and a manageable safety profile in RRMM patients, suggesting potential for future research and clinical application.

Limitations:
  • Small sample size and short follow-up duration.
  • Lack of a control group for comparative analysis, which may introduce biases.
Conclusion:

The combination therapy demonstrates significant anti-tumor activity with a manageable safety profile, warranting further investigation in larger studies.

Original Source(s)

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

  • by Rakesh Popat, Bradley Augustson, Mercedes Gironella, Cindy Lee, Paul Cannell, Nashita Patel, Ravi S. Kasinathan, Rachel Rogers, Mehreen Shaikh, Amy Curry, Fernando Carreño, Sumita Roy-Ghanta, Joanna Opalinska, Hang Quach

  • October 21, 2024

Related Content

Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence

Romiplostim N01 Enhances Platelet Recovery in Autologous Stem Cell Transplantation with Non-Cryopreserved Peripheral Blood Stem Cells for Plasma Cell Disorders

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis